Fareston (toremifene)
- Region
- 🇪🇺 EU
- Active substance
- toremifene
- Company
- Orion Corporation
- Status
- Authorised
- Therapeutic area
- Breast Neoplasms
- CHMP opinion
- Tue 17 Oct 1995
- EU approval
- Wed 14 Feb 1996
- Application
- EMEA/H/C/000091
- ATC
- L02BA02
- Official record
- www.ema.europa.eu
Indication
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours.
Regulatory milestones
No milestones recorded in the last year.
Follow Fareston
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.